Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

  Рет қаралды 12,907

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
1:19:35
U.S. Food and Drug Administration
Рет қаралды 28 М.
Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
54:28
U.S. Food and Drug Administration
Рет қаралды 16 М.
99.9% IMPOSSIBLE
00:24
STORROR
Рет қаралды 31 МЛН
Designing First-In-Human Trials for Small Molecules and Biologics
37:34
U.S. Food and Drug Administration
Рет қаралды 11 М.
Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
33:18
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
1:20:20
Getting the Best Dose: The Clinical Pharmacology Studies that Help Achieve this Goal
48:50
U.S. Food and Drug Administration
Рет қаралды 4,6 М.
Navigating the World of Combination Products (2of15) REdI - May 29-30, 2019
1:14:28
U.S. Food and Drug Administration
Рет қаралды 9 М.
Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017
46:00
U.S. Food and Drug Administration
Рет қаралды 21 М.
FDA Drug Manufacturing Inspections - REdI 2020
52:33
U.S. Food and Drug Administration
Рет қаралды 9 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
U.S. Food and Drug Administration
Рет қаралды 1,3 М.
Office of Clinical Pharmacology (OCP): Drugs and Biologics - Bioanalysis 2020
21:10
U.S. Food and Drug Administration
Рет қаралды 2,7 М.